SPOTLIGHT: Merck sub-licenses Cubicin in Japan


A Japanese subsidiary of Merck has licensed Cubist's antibiotic Cubicin. Cubist gains $6 million up front for the Japanese rights and will get up to $39.5 million more in milestones for a successful development program. Release